Save time and jump to the most important pieces.
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
10-Q - GALECTIN THERAPEUTICS INC (0001133416) (Filer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
SC 13D/A - GALECTIN THERAPEUTICS INC (0001133416) (Subject)
HC Wainwright & Co. reiterated coverage of Galectin Therapeutics with a rating of Buy and set a new price target of $14.00 from $12.00 previously
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)
The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Bespoke Extracts The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 3,000 shares at an average price of $0.07. To acquire these shares, it cost around $210. What's Happening: The company's stock jumped around 51% o
Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S.
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. About Galectin TherapeuticsGalectin Therapeutics is dedicated to d
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a company presentation on September 9, 2024 at 12:00 PM ET. The webcast of the presentation can be accessed here or through the Company's website on the Events & Presentation page of the investors section. Additionally, Galectin management team will be available for on
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company's clinical, regulatory, and operational efforts across its ongoing programs in c
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S.
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, "We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertensi
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This quarter we remai
Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr